Navigation Links
New study: Pine bark reduces perimenopausal symptoms
Date:8/28/2007

A study to be published in an upcoming edition of the Scandinavian Journal of Obstetrics and Gynaecology reveals that Pycnogenol (pic-noj-en-all), pine bark extract from the French maritime pine tree, reduces climacteric symptoms such as hot flashes, depression, panic attacks, cholesterol and other common symptoms associated with women entering menopause transition. The results suggest Pycnogenol may serve as an alternative treatment to estrogen replacement therapy, which is the most common remedy of pre-menopause (perimenopausal) symptoms.

According to the U.S. Department of Health and Human Services, perimenopause is the natural part of aging that signals the ending of a womans reproductive years. It marks the time when a womans body begins its move into menopause and can last anywhere from two to eight years.

Pycnogenol was chosen for this study due to previous research revealing health benefits associated with cognitive function, skin elasticity, nitric oxide stimulation, free radical scavenging and the broadening of antioxidant activity, said Dr. Peter Rohdewald, Institute of Pharmaceutical Chemistry at Germanys University of Munster and a lead researcher of this study. Achieving these health benefits is key to treating perimenopausal symptoms naturally.

The randomized, double-blind, placebo controlled study was conducted at Ham-Ming Hospital in Taiwan with 155 perimenopausal women. Each day, patients either received 200 mg Pycnogenol or placebo, and recorded their symptoms using the Womens Health Questionnaire (WHQ). The WHQ consisted of the following: somatic symptoms, depressed mood, vasomotoric symptoms, memory/concentration, attractiveness, anxiety, sexual behavior, sleep problems and menstrual symptoms.

Additionally, patients visited the clinic at one, three and six months following start of treatment. At each visit, BMI, blood pressure, lipid profile and total antioxidant status were recorded.

After six months, LDL (bad) cholesterol dropped by 10 percent with Pycnogenol treatment compared to placebo. Patients who supplemented with Pycnogenol also had increased antioxidant levels compared to the placebo group. During treatment, rapid improvement of symptoms was reported from the Pycnogenol group after one month. All symptoms of the WHQ improved significantly compared to the start of treatment, and patients did not report unwanted side effects. In the placebo group, no significant changes of symptoms were recorded.

There is a shift away from the use of hormone replacement therapy due to side effects and in its absence women are searching for safe and natural options to help manage their symptoms. This study investigating Pycnogenol as a potential natural alternative is very encouraging in view of the safety of Pycnogenol as it does not bear any hormone-like activities at all, said Dr. Rohdewald.

Numerous other published studies reveal Pycnogenols effectiveness for womens health, such as relieving menstrual pain and endometriosis, and it is patent-protected for this application. Additional studies reveal Pycnogenol is a natural anti-inflammatory, which provides the basis for the rationale to use Pycnogenol to naturally moderate inflammatory pain sensation involved in menstruation.


'/>"/>

Contact: Melanie Nimrodi
mnimrodi@mww.com
312-546-3508
MWW Group
Source:Eurekalert

Related medicine news :

1. Counter study: cholesterol drugs no good in preventing colon cancer
2. A strategic study: Soy diet makes heart disease to worsen in male mice
3. Bird Flu Pandemic Study: Clerical & Support Staff May Stay At Home
4. Study: Older Pancreatic Cancer Surgery Survivors Live Long
5. New Study: Pine Bark Significantly Reduces Endometriosis
6. Stress reduces your immunity- startling but true!!!!!
7. Thirty minutes of work up per day reduces the risk of Diabetes
8. Aspirin reduces deaths
9. Tomato Sauce reduces Cancer Risk- Study
10. Calcium reduces colon cancer risk
11. New pacemaker reduces risk of heart failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: